Abstract
Cisplatin-based neoadjuvant chemotherapy prior to radical cystectomy is standard in fit patients. Inactivating mutations of the nucleotide excision repair gene ERCC2 can predict response to cisplatin-based chemotherapy. Evaluation of the functional impact of ERCC2 mutations can provide mechanistic frameworks supporting the potential predictive role of ERCC2 loss of function.
See related article by Li et al., p. 977
- Received September 5, 2018.
- Revision received October 30, 2018.
- Accepted November 13, 2018.
- Published first November 19, 2018.
- ©2018 American Association for Cancer Research.
Log in using your username and password
Purchase Short Term Access
Pay Per Article - You may access this article (from the computer you are currently using) for 1 day for US$35.00
Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.
February 2019
Volume 25, Issue 3
Volume 25, Issue 3
DNA Damage Response Gene Alterations in Urothelial Cancer: Ready for Practice?
Jump to section
Advertisement